Stephen Paul Joins as CEO of Voyager Therapeutics

Voyager Therapeutics, the Cambridge, MA-based gene therapy company launched by Third Rock Ventures earlier this year (see Feb 2014 news story), has appointed Stephen Paul, M.D. as its new CEO. Interim CEO Mark Levin, a Partner at Third Rock Ventures (TRV), will now become Chairman of the Board of Directors. Dr. Paul has a track record of over 35 years in neuroscience research, including CNS drug discovery and development. Prior to his role as Venture Partner at TRV, Dr. Paul spent 17 years at Eli Lilly and Company in key leadership roles. Voyager Therapeutics is developing adeno-associated viral (AAV) approaches to treat disorders of the central nervous system, including familial ALS caused by SOD1 mutations.

Voyager Therapeutics, the Cambridge, MA-based gene therapy company launched by Third Rock Ventures earlier this year (see Feb 2014 news story), has appointed Stephen Paul, M.D. as its new CEO. Interim CEO Mark Levin, a Partner at Third Rock Ventures (TRV), will now become Chairman of the Board of Directors. Dr. Paul has a track record of over 35 years in neuroscience research, including CNS drug discovery and development. Prior to his role as Venture Partner at TRV, Dr. Paul spent 17 years at Eli Lilly and Company in key leadership roles. Voyager Therapeutics is developing adeno-associated viral (AAV) approaches to treat disorders of the central nervous system, including familial ALS caused by SOD1 mutations.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail